The top three molecular diagnostics companies in the US in 2026 are Cepheid, bioMérieux and Roche Diagnostics.
That ranking is based on iData Research market share data for the U.S. molecular diagnostics market in 2025.
Molecular diagnostics is the largest and fastest-growing segment of a U.S. in vitro diagnostics (IVD) market that iData Research valued at $23.9 billion in 2025.
This guide explains who leads, which systems they sell and what each company has done in the past year.
Find growth niches in minutes, not months.
Explore quick, actionable insights from the select markets.
Table of Contents
➜ Who are the top molecular diagnostics companies in the US in 2026
➜ Why Cepheid leads the molecular diagnostics market
➜ What makes bioMérieux a top molecular diagnostics company
➜ How Roche Diagnostics ranks in molecular diagnostics
➜ How big is the US in vitro diagnostics market
➜ What trends are shaping molecular diagnostics
Key Takeaways
- Cepheid ranked first in the U.S. molecular diagnostics market in 2025, led by its GeneXpert systems.
- bioMérieux ranked second, with the BIOFIRE FilmArray near-patient analyzer and the SPOTFIRE point-of-care analyzer.
- Roche Diagnostics ranked third, anchored by its high-throughput cobas 6800/8800 systems.
- Molecular diagnostics is the largest and fastest-growing segment of the U.S. IVD market.
- iData Research forecasts the total U.S. IVD market to grow from $23.9 billion in 2025 to $31.8 billion at a 4.2% CAGR.
Who are the top molecular diagnostics companies in the US in 2026
The three leaders in U.S. molecular diagnostics are Cepheid, bioMérieux and Roche Diagnostics.
Molecular diagnostics tests look for genetic material, such as DNA or RNA, to identify infections and other conditions.
The ranking below reflects 2025 market share in the U.S. In Vitro Diagnostics Market report from iData Research.
- Cepheid
- bioMérieux
- Roche Diagnostics
Cepheid and bioMérieux also hold the top two places in the overall U.S. IVD market, as covered in our guide to the biggest in vitro diagnostics market companies in 2026.
Why Cepheid leads the molecular diagnostics market
Cepheid, a Danaher company, was the leading company in both U.S. molecular diagnostics and the wider U.S. IVD market in 2025.
Its GeneXpert line is popular because it lets labs run a wide range of tests on a single machine.
The systems also offer long walk-away time, which frees staff for other work while tests run.
GeneXpert models are available for both point-of-care and near-patient settings.
On January 20, 2026, Cepheid received FDA clearance for its Xpert GI Panel, which detects 11 gastrointestinal pathogens from one stool sample in about 74 minutes.
In July 2026, the company announced a third-generation GeneXpert system and unveiled it at the ADLM 2026 meeting.
Cepheid says the new system is still in development and is designed to run its existing FDA-cleared test menu.
What makes bioMérieux a top molecular diagnostics company
bioMérieux ranked second in U.S. molecular diagnostics in 2025 and second in the overall U.S. IVD market.
The company has a significant molecular portfolio, including the BIOFIRE FilmArray near-patient analyzer and the BIOFIRE SPOTFIRE point-of-care analyzer.
In September 2025, bioMérieux won FDA clearance and a CLIA waiver to use anterior nasal swabs on the SPOTFIRE Respiratory/Sore Throat Panel Mini, which returns results in about 15 minutes.
That panel checks one sample for rhinovirus, influenza A, influenza B, RSV, SARS-CoV-2 and Streptococcus pyogenes.
On June 26, 2026, the company filed a dual 510(k) and CLIA waiver application for the SPOTFIRE Vaginitis Panel.
That panel is still pending FDA clearance and is designed to deliver results at the point of care in about 20 minutes.
How Roche Diagnostics ranks in molecular diagnostics
Roche Diagnostics ranked third in the U.S. molecular diagnostics market in 2025.
Roche also ranked third in U.S. molecular blood donor screening, a related segment iData Research tracks separately.
Its cobas 6800/8800 systems serve large labs that need to process high volumes of molecular tests.
In December 2025, Roche launched cobas 6800/8800 systems version 2.0 with software version 2.0.1, according to iData Research.
The update is designed to help labs optimize resources, reduce downtime, consolidate test menus and increase throughput.
On July 24, 2026, Roche received FDA 510(k) clearance for its cobas BV/CV assay, a PCR test for bacterial vaginosis and Candida vaginitis.
The assay runs on the cobas 6800/8800 systems, and Roche plans to add the cobas 5800 system later in 2026.
How big is the US in vitro diagnostics market
iData Research valued the U.S. in vitro diagnostics market at $23.9 billion in 2025.
The market is expected to reach $31.8 billion by 2032, growing at a CAGR of 4.2%.
Molecular diagnostics is the largest and fastest-growing of the eight segments in the report.
The other segments are immunochemistry, urinalysis, molecular blood donor screening, hematology, hemostasis, point-of-care blood gas diagnostics and point-of-care blood glucose monitoring.
For more on the decentralized side of testing, see our breakdown of point of care testing in the U.S.
What trends are shaping molecular diagnostics
Automation and decentralized testing are among the strongest drivers of the U.S. IVD market, according to iData Research.
Faster point-of-care molecular tests are a big part of that shift.
A 2026 literature review in Diagnostics found that newer molecular point-of-care tests for respiratory infections now rival lab-based testing in accuracy, with results in roughly 15 to 80 minutes.
A 2026 meta-analysis in eClinicalMedicine found these tests shortened the time to appropriate antibiotic treatment by about 8 hours, though they did not meaningfully reduce overall antibiotic use.
Liquid biopsy and next-generation sequencing are also expanding molecular testing into cancer detection and precision medicine.
Dealmaking is reshaping the space as well, with Abbott completing its acquisition of Exact Sciences in March 2026.
Pricing pressure and the high cost of instruments and reagents remain the main limits on growth, especially for smaller labs.
Frequently asked questions
Who is the largest molecular diagnostics company in the US?
Cepheid is the largest molecular diagnostics company in the U.S. by market share in 2025, according to iData Research.
What are the top 3 molecular diagnostics companies?
They are Cepheid, bioMérieux and Roche Diagnostics, based on 2025 U.S. market share data from iData Research.
What is molecular diagnostics used for?
Molecular diagnostics detects DNA or RNA to identify infectious diseases, genetic disorders and cancers.
Is molecular diagnostics the fastest-growing IVD segment?
Yes, iData Research identifies molecular diagnostics as the largest and fastest-growing segment of the U.S. IVD market.
How big is the US in vitro diagnostics market?
The U.S. IVD market was valued at $23.9 billion in 2025 and is forecast to reach $31.8 billion at a 4.2% CAGR.
Turn market painpoints into opportunities
Explore how procedure trends and competitor positioning create clear openings for industry experts in the market.
